Natixis Advisors LLC lowered its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 31.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,537 shares of the company's stock after selling 7,160 shares during the quarter. Natixis Advisors LLC's holdings in Vaxcyte were worth $1,272,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Whipplewood Advisors LLC bought a new position in Vaxcyte in the fourth quarter worth approximately $28,000. Smartleaf Asset Management LLC raised its position in shares of Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after purchasing an additional 260 shares during the period. Blue Trust Inc. lifted its holdings in shares of Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after purchasing an additional 371 shares in the last quarter. Assetmark Inc. grew its position in Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after purchasing an additional 775 shares during the period. Finally, Nomura Asset Management Co. Ltd. bought a new stake in Vaxcyte during the 3rd quarter valued at $92,000. Institutional investors and hedge funds own 96.78% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on the stock. Guggenheim reiterated a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, March 12th. The Goldman Sachs Group initiated coverage on Vaxcyte in a research note on Friday, December 20th. They set a "buy" rating and a $135.00 price target for the company. Finally, Needham & Company LLC reissued a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, February 26th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $147.50.
Check Out Our Latest Research Report on PCVX
Vaxcyte Price Performance
Shares of NASDAQ PCVX traded down $1.31 during midday trading on Friday, reaching $69.46. The company's stock had a trading volume of 660,934 shares, compared to its average volume of 980,702. The stock has a market capitalization of $8.94 billion, a P/E ratio of -15.10 and a beta of 1.02. The firm has a 50 day moving average price of $80.07 and a 200-day moving average price of $92.52. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. On average, equities analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.
Insider Buying and Selling
In related news, Director Teri Loxam sold 6,250 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the sale, the director now directly owns 7,175 shares in the company, valued at approximately $610,664.25. This represents a 46.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the completion of the transaction, the chief operating officer now owns 205,695 shares of the company's stock, valued at $17,208,443.70. This represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,250 shares of company stock valued at $3,840,018. 3.10% of the stock is owned by insiders.
Vaxcyte Company Profile
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
See Also
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
